MedTrace Logo

Study to ONO-4538 in Patients With Rhabdoid Tumor

NCT06622941 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-03-12

No results posted yet for this study

Summary

Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors

Conditions

  • Rhabdoid Tumor

Interventions

DRUG

ONO-4538

every 2 weeks

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Project Leader · Ono Pharmaceutical Co. Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-25
Primary Completion
2029-01-31
Completion
2030-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06622941 on ClinicalTrials.gov